IP Library Granted Patent US 12,173,368
Granted Patent B2
US 12,173,368 · App. 18/298,291 · Granted Dec 24, 2024

Compositions and analysis of dephosphorylated oligoribonucleotides

Inventors: Ivan R. Correa, Jr. (Hamilton, MA); Eric Wolf (Manchester, MA); Nan Dai (Ipswich, MA); Erbay Yigit (Boxford, MA); Sebastian Grünberg (Salem, MA)
Assignee: New England Biolabs, Inc.
C12Q1/6872C12Y301/13005C12Q1/6806C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,173,368
App. No.
18/298,291
Granted
Dec 24, 2024
Kind
B2
Abstract

The present disclosure relates, according to some embodiments, to compositions and analysis of RNA (e.g., dephosphorylated oligoribonucleotides) including, for example, natural and/or synthetic RNAs. A composition may comprise, for example, an endoribonuclease having an amino acid sequence that (i) corresponds to an amino acid sequence of a first species (e.g., Homo sapiens, Escherichia coli, Aspergillus oryzae, Momordica charantia, Pyrococcus furiosus, Cucumis sativus , and Sus scrofa ) or (ii) is a non-naturally occurring sequence; and/or an RNA end repair enzyme having an amino acid sequence that (i) corresponds to an amino acid sequence of a species other than the first species (e.g., a bacterial species or a bacteriophage species) or (ii) is a non-naturally occurring sequence.

Claims (11)

1. A composition comprising:

(a) a human RNase 4 in an amount having catalytic activity equivalent to 100 to 10,000 units of RNase T1, wherein one unit of RNase T1 causes an increase in absorbance of 1.0 at 260 nm in 15 minutes when yeast RNA is hydrolyzed at 37° C. and pH 7.5 in a reaction comprising 50 mM Tris-HCl, 2 mM EDTA, and 3 mg/mL of the yeast RNA;

(b) a bacterial RNA end repair enzyme or a bacteriophage RNA end repair enzyme; and

(c) an RNA comprising at least 1,000 nucleotides in an amount of 0.01 μg to 100 μg, wherein the human RNase 4 specificity is selected from (1) cleavage after a specific nucleotide followed by a purine, (2) cleavage after a specific nucleotide followed by a pyrimidine,

(3) cleavage after a purine followed by a specific nucleotide, and (4) cleavage after a pyrimidine followed by a specific nucleotide; and

wherein the RNA end repair enzyme comprises phosphodiesterase and phosphomonoesterase activities.

2. A composition according to claim 1 , wherein the human RNase 4 cleaves on average once every 6-12 nucleotides.

3. A composition according to claim 1 , wherein the RNA end repair enzyme is present in an amount of 10 units to 100,000 units.

4. The composition according to claim 1 , wherein the RNA end repair enzyme is a T4 polynucleotide kinase-phosphatase or a Cth polynucleotide kinase-phosphatase.

5. The composition according to claim 1 further comprising one or more of a denaturing agent, a buffering agent, and an RNA substrate.

6. A composition according to claim 1 , wherein the RNA comprises messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small RNA (sRNA), microRNA (miRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), aptamer RNA, antisense RNA, silencing RNA (siRNA), guide RNA (gRNA), or any combination thereof.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2023
From: CORREA, IVAN R., JR; WOLF, ERIC J.; DAI, NAN; YIGIT, ERBAY; GRUNBERG, SEBASTIAN
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 063289/0343 →
Continuity (4)
Continuation In Part 18182122 · Mar 10, 2023
Provisional Application 63329262 · Apr 8, 2022
Provisional Application 63319157 · Mar 11, 2022
Related Publication 20230287489A1 · Sep 14, 2023